{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:40:50Z","timestamp":1789184450521,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40272-025-00725-2","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T19:20:15Z","timestamp":1761679215000},"page":"69-81","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data"],"prefix":"10.1007","volume":"28","author":[{"given":"Herta","family":"Crauwels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ringold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Hartingsveldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meg","family":"Jett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Baguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8627-6512","authenticated-orcid":false,"given":"Jocelyn H.","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"238","key":"725_CR1","first-page":"127","volume":"62","author":"DD Gladman","year":"1987","unstructured":"Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)\u2013an analysis of 220 patients. QJM. 1987;62(238):127\u201341.","journal-title":"QJM"},{"issue":"3","key":"725_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3899\/jrheum.160717","volume":"44","author":"D Zisman","year":"2017","unstructured":"Zisman D, Gladman DD, Stoll ML, Strand V, Lavi I, Hsu JJ, et al. The juvenile psoriatic arthritis cohort in the CARRA registry: clinical characteristics, classification, and outcomes. J Rheumatol. 2017;44(3):342\u201351.","journal-title":"J Rheumatol"},{"issue":"5","key":"725_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/rheumatology\/kead370","volume":"63","author":"JM Low","year":"2024","unstructured":"Low JM, Hyrich KL, Ciurtin C, McErlane F, Wedderburn LR, Geifman N, et al. The impact of psoriasis on wellbeing and clinical outcomes in juvenile psoriatic arthritis. Rheumatology (Oxford). 2024;63(5):1273\u201380.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"725_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","volume":"17","author":"LC Coates","year":"2017","unstructured":"Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65\u201370.","journal-title":"Clin Med (Lond)"},{"issue":"9563","key":"725_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","volume":"369","author":"A Ravelli","year":"2007","unstructured":"Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369(9563):767\u201378.","journal-title":"Lancet"},{"issue":"5","key":"725_CR6","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/BOR.0b013e328348b278","volume":"23","author":"ML Stoll","year":"2011","unstructured":"Stoll ML, Punaro M. Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. Curr Opin Rheumatol. 2011;23(5):437\u201343.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"725_CR7","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"key":"725_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.884727","volume":"10","author":"F Brunello","year":"2022","unstructured":"Brunello F, Tirelli F, Pegoraro L, Dell\u2019Apa F, Alfisi A, Calzamatta G, et al. New insights on juvenile psoriatic arthritis. Front Pediatr. 2022;10:884727.","journal-title":"Front Pediatr"},{"issue":"10","key":"725_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"4","key":"725_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/2475530318799072","volume":"3","author":"TG Brandon","year":"2018","unstructured":"Brandon TG, Manos CK, Xiao R, Ogdie A, Weiss PF. Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities. J Psoriasis Psoriatic Arthritis. 2018;3(4):131\u20136.","journal-title":"J Psoriasis Psoriatic Arthritis."},{"key":"725_CR11","doi-asserted-by":"crossref","unstructured":"F. Oliveira-Ramos, M. Eusebio, M.M. F, A.F. Mourao, C. Furtado, R. Campanilho-Marques, I. Cordeiro, J. Ferreira, M. Cerqueira, R. Figueira, I. Brito, H. Canhao, M.J. Santos, J.A. Melo-Gomes, J.E. Fonseca. Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. 2016;2(2):e000304.","DOI":"10.1136\/rmdopen-2016-000304"},{"issue":"6","key":"725_CR12","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, Angeles-Han ST, Beukelman T, Lovell D, Cuello CA, Becker ML, et al. 2019 American College of Rheumatology\/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717\u201334.","journal-title":"Arthritis Care Res (Hoboken)."},{"issue":"1","key":"725_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/art.40350","volume":"70","author":"PA Nigrovic","year":"2018","unstructured":"Nigrovic PA, Raychaudhuri S, Thompson SD. Review: genetics and the classification of arthritis in adults and children. Arthritis Rheumatol. 2018;70(1):7\u201317.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"725_CR14","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","volume":"47","author":"F Cantini","year":"2008","unstructured":"Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology (Oxford). 2008;47(6):872\u20136.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"725_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-020-02380-z","volume":"23","author":"K Murray","year":"2021","unstructured":"Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, et al. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther. 2021;23(1):25.","journal-title":"Arthritis Res Ther"},{"key":"725_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2147\/TCRM.S4908","volume":"5","author":"NB Silverberg","year":"2009","unstructured":"Silverberg NB. Pediatric psoriasis: an update. Ther Clin Risk Manag. 2009;5:849\u201356.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"725_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdermsci.2009.01.003","volume":"54","author":"N Yawalkar","year":"2009","unstructured":"Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci. 2009;54(2):99\u2013105.","journal-title":"J Dermatol Sci"},{"issue":"1","key":"725_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/14712598.2021.1938538","volume":"22","author":"R Mohanakrishnan","year":"2022","unstructured":"Mohanakrishnan R, Beier S, Deodhar A. IL-23 inhibition for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2022;22(1):59\u201365.","journal-title":"Expert Opin Biol Ther"},{"key":"725_CR19","unstructured":"Janssen Biotech, Inc. TREMFYA [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761061s028s029lbl.pdf. Revised September 2025. Accessed 14 Oct 2025."},{"key":"725_CR20","unstructured":"AbbVie Inc. SKYRIZI [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761105s029,761262s007lbl.pdf. Revised June 2024. Accessed 22 July 2025."},{"key":"725_CR21","unstructured":"Sun Pharmaceutical Industries, Inc. ILUMYA [package insert]. U.S. Food and Drug Adminsitration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761067s018lbl.pdf. Revised April 2024. Accessed 22 July 2025."},{"issue":"1","key":"725_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","volume":"82","author":"A Menter","year":"2020","unstructured":"Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161\u2013201.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"725_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40272-022-00533-y","volume":"24","author":"JH Leu","year":"2022","unstructured":"Leu JH, Shiff NJ, Clark M, Bensley K, Lomax KG, Berezny K, et al. Intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis and juvenile psoriatic arthritis and subcutaneous ustekinumab in patients with juvenile psoriatic arthritis: extrapolation of data from studies in adults and adjacent pediatric populations. Paediatr Drugs. 2022;24(6):699\u2013714.","journal-title":"Paediatr Drugs"},{"key":"725_CR24","doi-asserted-by":"publisher","first-page":"232470962312004","DOI":"10.1177\/23247096231200403","volume":"11","author":"MC Nelson","year":"2023","unstructured":"Nelson MC, Manos CK. Secukinumab therapy in refractory juvenile idiopathic arthritis. J Investig Med High Impact Case Rep. 2023;11:23247096231200404.","journal-title":"J Investig Med High Impact Case Rep."},{"issue":"5","key":"725_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/acr.25465","volume":"77","author":"HI Brunner","year":"2024","unstructured":"Brunner HI, Shmagel A, Horneff G, Foeldvari I, Anton J, Ramanan AV, et al. Pharmacokinetics, efficacy, and safety of upadacitinib in pediatric patients with polyarticular-course juvenile idiopathic arthritis: an interim analysis of an open-label, phase 1 trial. Arthritis Care Res (Hoboken). 2024;77(5):584\u201393.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"11","key":"725_CR26","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1136\/ard-2023-225094","volume":"83","author":"HI Brunner","year":"2024","unstructured":"Brunner HI, Akikusa JD, Al-Abadi E, Bohnsack JF, Boteanu AL, Chedeville G, et al. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: preliminary results of an open-label, long-term extension study. Ann Rheum Dis. 2024;83(11):1561\u201371.","journal-title":"Ann Rheum Dis"},{"key":"725_CR27","unstructured":"Amgen Inc. OTEZLA [package insert]. U.S. Food and Drug Administration website. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/205437s014lbl.pdf Revised July 2025. Accessed 5 Aug 2025."},{"key":"725_CR28","unstructured":"European Medicines Agency - Committee for Medicinal Products for Human Use. Summary of opininon (post authorisation) Taltz ixekizumab. Updated July 24, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-taltz-ii-53_en.pdf. Accessed 7 Aug 2025."},{"issue":"6","key":"725_CR29","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1586\/ecp.09.40","volume":"2","author":"SE Kern","year":"2009","unstructured":"Kern SE. Challenges in conducting clinical trials in children: approaches for improving performance. Expert Rev Clin Pharmacol. 2009;2(6):609\u201317.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"725_CR30","doi-asserted-by":"publisher","first-page":"e1242","DOI":"10.1542\/peds.2010-3487","volume":"128","author":"J Dunne","year":"2011","unstructured":"Dunne J, Rodriguez WJ, Murphy MD, Beasley BN, Burckart GJ, Filie JD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011;128(5):e1242\u20139.","journal-title":"Pediatrics"},{"key":"725_CR31","unstructured":"United States Food and Drug Administration. Specific requirements on content and format of labeling for human prescription drugs; revision of \"pediatric use'' subsection in the labeling; final rule. 1994. https:\/\/www.federalregister.gov\/documents\/1994\/12\/13\/94-30238\/specific-requirements-on-content-and-format-of-labeling-for-human-prescription-drugs-revision-o. Accessed 3 Mar 2025."},{"key":"725_CR32","unstructured":"United States Food and Drug Administration. E11A Pediatric extrapolation. 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e11a-pediatric-extrapolation. Accessed 7 Apr 2025."},{"issue":"10","key":"725_CR33","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/art.42534","volume":"75","author":"LE Schanberg","year":"2023","unstructured":"Schanberg LE, Mulugeta LY, Akinlade B, Brunner HI, Chen J, Colbert RA, et al. Therapeutic development in polyarticular course juvenile idiopathic arthritis: extrapolation, dose selection, and clinical trial design. Arthritis Rheumatol. 2023;75(10):1856\u201366.","journal-title":"Arthritis Rheumatol"},{"key":"725_CR34","unstructured":"European Medicines Agency. ICH guideline E11A on pediatric extrapolation\u2014Scientific guideline. 2025. https:\/\/www.ema.europa.eu\/en\/ich-guideline-e11a-pediatric-extrapolation-scientific-guideline. Accessed 7 Apr 2025."},{"key":"725_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1532852","volume":"16","author":"K Sachen","year":"2025","unstructured":"Sachen K, Hammaker D, Sarabia I, Stoveken B, Hartman J, Leppard K, et al. Guselkumab binding to CD64+ IL-23\u2013producing myeloid cells enhances potency for neutralizing IL-23 signaling. Front Immunol. 2025;16:1532852.","journal-title":"Front Immunol"},{"issue":"3","key":"725_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"725_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"10230","key":"725_CR38","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"10230","key":"725_CR39","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"4","key":"725_CR40","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/bjd\/ljae502","volume":"192","author":"VH Prajapati","year":"2025","unstructured":"Prajapati VH, Seyger MMB, Wilsmann-Theis D, Szakos E, Kaszuba A, van Hartingsveldt B, et al. Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study. Br J Dermatol. 2025;192(4):618\u201328.","journal-title":"Br J Dermatol"},{"issue":"3","key":"725_CR41","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"725_CR42","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.41390","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, Schanberg LE, Kimura Y, Dennos A, Co DO, Colbert RA, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72(11):1945\u201351.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"725_CR43","first-page":"S12","volume":"20","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis GE, Siebert S. The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis. Musculoskelet Care. 2022;20(Suppl 1):S12-21.","journal-title":"Musculoskelet Care"},{"key":"725_CR44","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ard.2025.05.397","volume":"84","author":"PJ Mease","year":"2025","unstructured":"Mease PJ, Ritchlin CT, Coates LC, Kollmeier A, Zhou B, Jiang Y, et al. Inhibition of structural damage progression with guselkumab, a selective IL-23i, in participants with active PsA: results through week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study. Ann Rheum Dis. 2025;84:321\u20132.","journal-title":"Ann Rheum Dis"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00725-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:40:42Z","timestamp":1770043242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["725"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00725-2","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: A typo in the second point of the key points \"United States\" has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HC, SR, SH, BVH, VS, MJ, TB, EA, SDC, JHL: Employee: Johnson & Johnson; Shareholder: Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All studies included in these analyses were conducted in accordance with the ethical principles originating in the Declaration of Helsinki, International Council for Harmonisation (ICH) Good Clinical Practice guidelines, and applicable regulatory requirements and in compliance with the respective protocols. The studies were approved by an independent ethics committee or institutional review board at each participating site. Ethics committee approval was obtained for all original studies included in these analyses, and detailed information is available in their respective publications [\n                      \n                      \u2013\n                      \n                      ].","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Adult participants signed a written consent form. For participants under the age of 18\u00a0years, parents or a legal guardian provided written informed consent and participants provided written age-appropriate assent prior to the conduct of study assessments, examinations, or procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sharing policy of Johnson & Johnson is available at\n                      \n                      . As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access [YODA] Project site at\n                      \n                      .","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability Statement"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study design: JHL. Analyzing data: HC, JHL, VS, BvH. Interpreting data: HC, SDC, TB, JHL, SR, SH, BVH, MJ, EA. Writing\/revising the manuscript: HC, SDC, TB, JHL, VS, SR, SH, BVH, MJ, EA. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}